LMNB1 and hepatocellular carcinoma: Addition of plasma lamin B1 mRNA to the current standard tests for diagnosis of HCC as a new diagnostic and screening tool could greatly improve the ability to identify such patients and thus could allow them to benefit from earlier treatment.